{"id":827468,"date":"2025-03-19T08:18:02","date_gmt":"2025-03-19T12:18:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/"},"modified":"2025-03-19T08:18:02","modified_gmt":"2025-03-19T12:18:02","slug":"cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/","title":{"rendered":"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services"},"content":{"rendered":"
\n

\n
\n Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML<\/i>
\n <\/b>\n <\/p>\n

SOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (\u201cCERo\u201d or the \u201cCompany\u201d) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces an agreement with the University of California Davis for the manufacturing of CER-1236 to be used in the Company\u2019s upcoming Phase 1 clinical trial for Acute Myeloid Leukemia (AML).\u00a0 The Company believes it is on track for dosing the first patient in the first half of 2025. <\/p>\n

CEO Chris Ehrlich commented, \u201cThe precision and compliance in manufacturing is critical to successful development and execution of clinical trials and UC Davis is a leading institution with an impeccable reputation in this area.\u00a0 The manufacturing of product is among the final steps necessary to have completed prior to patient dosing, and we are looking forward to continuing to drive the process forward.\u201d<\/p>\n

\n About CERo Therapeutics Holdings, Inc.<\/b>\n <\/p>\n

CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body\u2019s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (\u201cCER-T\u201d). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (\u201cCAR-T\u201d) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies.<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo the timing and completion of the reverse stock split, and the acceptance and implementation of its proposed plan of compliance with Nasdaq continued listing standards. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201cwould\u201d and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo\u2019s management.<\/p>\n

Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo\u2019s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The risks described in CERo\u2019s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\n Contact:<\/b>
\n
Chris Ehrlich
Chief Executive Officer
chris@cero.bio<\/a><\/u><\/p>\n

\n Investors:<\/b>
\n
CORE IR
investors@cero.bio<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML SOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (\u201cCERo\u201d or the \u201cCompany\u201d) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces an agreement with the University of California Davis for the manufacturing of CER-1236 to be used in the Company\u2019s upcoming Phase 1 clinical trial for Acute Myeloid Leukemia (AML).\u00a0 The Company believes it is on track for dosing the first patient in the first half of 2025. CEO Chris Ehrlich commented, \u201cThe precision and compliance in manufacturing is critical to successful … <\/p>\n

Continue reading “CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827468","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML SOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (\u201cCERo\u201d or the \u201cCompany\u201d) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces an agreement with the University of California Davis for the manufacturing of CER-1236 to be used in the Company\u2019s upcoming Phase 1 clinical trial for Acute Myeloid Leukemia (AML).\u00a0 The Company believes it is on track for dosing the first patient in the first half of 2025. CEO Chris Ehrlich commented, \u201cThe precision and compliance in manufacturing is critical to successful … Continue reading "CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T12:18:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njg2NyM2ODEyOTkyIzUwMDEyNDM5MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services\",\"datePublished\":\"2025-03-19T12:18:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/\"},\"wordCount\":746,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Njg2NyM2ODEyOTkyIzUwMDEyNDM5MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/\",\"name\":\"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Njg2NyM2ODEyOTkyIzUwMDEyNDM5MA==\",\"datePublished\":\"2025-03-19T12:18:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Njg2NyM2ODEyOTkyIzUwMDEyNDM5MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5Njg2NyM2ODEyOTkyIzUwMDEyNDM5MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/","og_locale":"en_US","og_type":"article","og_title":"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - Market Newsdesk","og_description":"Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML SOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (\u201cCERo\u201d or the \u201cCompany\u201d) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces an agreement with the University of California Davis for the manufacturing of CER-1236 to be used in the Company\u2019s upcoming Phase 1 clinical trial for Acute Myeloid Leukemia (AML).\u00a0 The Company believes it is on track for dosing the first patient in the first half of 2025. CEO Chris Ehrlich commented, \u201cThe precision and compliance in manufacturing is critical to successful … Continue reading \"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-19T12:18:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njg2NyM2ODEyOTkyIzUwMDEyNDM5MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services","datePublished":"2025-03-19T12:18:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/"},"wordCount":746,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njg2NyM2ODEyOTkyIzUwMDEyNDM5MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/","name":"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njg2NyM2ODEyOTkyIzUwMDEyNDM5MA==","datePublished":"2025-03-19T12:18:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njg2NyM2ODEyOTkyIzUwMDEyNDM5MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5Njg2NyM2ODEyOTkyIzUwMDEyNDM5MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-continues-to-progress-toward-initial-dosing-of-patients-in-phase-1-trial-with-agreement-with-university-of-california-davis-for-manufacturing-services\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827468"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827468\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}